PUNE, India, June 23, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Impetigo - Pipeline Review, H1 2016" market research report complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Impetigo and special features on late-stage and discontinued projects.
Complete report on H1 2016 pipeline review of Impetigo with 21 market data tables and 12 figures, spread across 46 pages is available at http://www.rnrmarketresearch.com/impetigo-pipeline-review-h1-2016-market-report.html
The report also reviews key players involved in the therapeutic development for Impetigo and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Impetigo Pipeline Review, H1 2016 report include Foamix Pharmaceuticals Ltd., Laboratories Ojer Pharma S.L., Lytix Biopharma AS and Toyama Chemical Co., Ltd. Drug profiles discussed in this research report are FMX-102, LTX-109, mupirocin, ozenoxacin and Synthetic Peptides for Infectious Disease.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Impetigo and reviews pipeline therapeutics for Impetigo by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Impetigo therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Impetigo therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Impetigo.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=617355
Reasons to buy: Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies; Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage ; Identify and understand important and diverse types of therapeutics under development for Impetigo; Identify potential new clients or partners in the target demographic; Develop strategic initiatives by understanding the focus areas of leading companies ; Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics; Devise corrective measures for pipeline projects by understanding Impetigo pipeline depth and focus of Indication therapeutics; Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope; Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Another newly published market research report titled on Migraine - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Companies discussed in this research are Achelios Therapeutics, Inc., Acorda Therapeutics, Inc., Afferent Pharmaceuticals, Inc., Alder Biopharmaceuticals Inc., Allergan Plc, Amgen Inc., Aralez Pharmaceuticals Inc., Astellas Pharma Inc., Biofrontera AG, Bristol-Myers Squibb Company, Charleston Laboratories, Inc., CoLucid Pharmaceuticals, Inc., Corium International, Inc., D-Pharm Ltd., Eli Lilly and Company, iCeutica, Inc., Impel NeuroPharma, Inc., Klaria Pharma Holding AB, Mallinckrodt Plc, Medestea Research & Production S.p.A., Merck & Co., Inc., Mithra Pharmaceuticals S.A., Monosol Rx, LLC, NAL Pharmaceuticals Ltd., Noxxon Pharma AG, Otsuka Holdings Co., Ltd., Pivot Pharmaceuticals Inc, Promius Pharma, LLC, RedHill Biopharma Ltd., Revance Therapeutics, Inc., Shin Nippon Biomedical Laboratories, Ltd., Suda Ltd, Teva Pharmaceutical Industries Ltd., TheraJect, Inc., Tonix Pharmaceuticals Holding Corp., Trevena, Inc., Trigemina, Inc., Vertex Pharmaceuticals Incorporated and Zosano Pharma Corporation. Migraine Pipeline market research report of 219 pages is available at http://www.rnrmarketresearch.com/migraine-pipeline-review-h1-2016-market-report.html
Explore more reports on Dermatology therapeutics
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE RnR Market Research